Skip to main content
OpenTrials
Completed

NCT Number: NCT03422471

Hypoglycemia and Autonomic Nervous System Function- B2

We will study the effect of hypoglycemia (low blood sugar) on baroreflex sensitivity in participants with well controlled type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

About this study

Participants are admitted for two days and two nights to an inpatient clinical research center for performance of study procedures. On Day 1, two hyperinsulinemic hypoglycemic (50 mg/dl) clamps are performed - an AM clamp from about 9 to 11 am and a PM clamp from about 1 to 3 pm.. Modified Oxford procedures are performed in duplicate at five time points -- before the AM clamp, during the AM clamp, before the PM clamp, during the PM clamp, and the morning of Day 2 (about 16 hrs after completion of the the PM clamp). The Modified Oxford procedure involves the sequential intravenous administration of nitroprusside and phenylephrine with assessment of blood pressure and heart rate by finapress. Baroreflex sensitivity is the relationship of changes in heart rate to changes in blood pressure. .

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females age 18 to 55 years
  • Type 2 Diabetes Mellitus controlled by diet, exercise and non-insulin glycemic control agents (metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors, alpha-glucosidase inhibitors or glucagon-like peptide-1 receptor agonist) or basal insulin at doses less than or equal to 0.3 units/ kg per day.

Exclusion criteria

  • Hemoglobin A1c > 9% for type 2 diabetes
  • Recurrent hypoglycemic episodes within the past month
  • BMI < 25 or > 42 (Type 2 diabetes only)
  • Pregnancy
  • Lactation
  • Clinically significant coronary artery, cerebrovascular, or peripheral vascular disease, or presence of systemic illness that might affect autonomic function. Such illnesses include congestive heart failure, renal, pulmonary, hepatic disease, anemia, malignancies, untreated thyroid disease, and alcoholism.
  • Current major depressive illness
  • In all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded.
  • Known hypersensitivity to nitroglycerin, nitroprusside and/or phenylephrine.
  • Blood pressure > 160/100 mmHg (applies to participants with T2 diabetes)
  • Creatinine > 1.5 mg/dL
  • Serum potassium >5.2 mmol/L
  • Estimated GFR < 50 mL/min
  • Use of Viagra, Cialis, and similar drugs within 72 hours of admission.
  • Use of beta-blockers or mineralocorticoid receptor antagonists

Treatment and study plan

Hyperinsulinemic Hypoglycemic Clamp

Other

Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.

Primary outcomes

  1. Modified Oxford Method Assessment of Baroreflex Function

    Time frame: Time 0 and 16 hours after hyperinsulinemic hypoglycemic clamps

    Change in baroreflex sensitivity between the first assessment (pre-AM clamp on Day 1) and the final assessment (AM of Day 2, about 16 hours after the PM clamp)

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Beth Israel Deaconess Medical Center
  • National Center for Advancing Translational Sciences (NCATS)
  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Hypoglycemia and Autonomic Nervous System Function

Acronym: HypoANS-B2

Important dates

Study start
2017
Primary completion
2025
Study completion
2025
First posted
Feb 5, 2018
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.